The Impact of the Inflation Reduction Act on Investment in Innovative Medicines: A Project-Level Analysis

Area of Science:

• Pharmaceutical Economics
• Drug Development
• Health Policy Analysis

Background:

• Debate persists regarding Medicare's price negotiation impact on pharmaceutical innovation and patient welfare.
• Existing policy simulations rely on elasticity estimates or structural models, potentially lacking real-world investor decision-making insights.
• Investor influence on advancing drug development programs necessitates a program-level analysis of investment decisions.

Purpose of the Study:

• To model the impact of Medicare price negotiation on the net present value (NPV) and investment decisions at key drug development stages.
• To incorporate investor decision-making factors not fully captured in current policy simulations.
• To provide a more realistic assessment of the long-term effects of pharmaceutical price negotiation on innovation.

Main Methods:

• Constructed a net present value (NPV) model using an illustrative case example.
• Analyzed investment decisions at six key timepoints during new drug development.
• Focused on factors influencing investor decision-making in the context of Medicare price negotiation.

Main Results:

• Medicare's price negotiation is projected to cause a 40% reduction in NPV at drug launch.
• Earlier development stages (preclinical, Phase 1) show greater NPV reduction due to expected dilution and discounting.
• This leads to earlier project discontinuation, particularly for small-molecule assets.

Conclusions:

• Medicare price negotiation significantly reduces drug development NPV, impacting investment decisions.
• The negative effects are more pronounced in early-stage development, suggesting a potentially larger long-term impact on innovation than previously estimated.
• Findings highlight the need for policy simulations to incorporate detailed investor decision-making models for accurate pharmaceutical innovation impact assessment.